Hims & Hers Health (NYSE:HIMS) Stock Gets Price Target Reduction from Jefferies Financial Group

Hims & Hers Health (NYSE:HIMS) had its price objective lowered by Jefferies Financial Group from $31.00 to $24.00 in a research report report published on Tuesday,Benzinga reports. Jefferies Financial Group currently has a hold rating on the stock.

Other equities research analysts have also issued reports about the company. Barclays decreased their price target on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research report on Friday, August 21st. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Morgan Stanley decreased their target price on Hims & Hers Health from $28.00 to $25.00 and set an “equal weight” rating on the stock in a report on Tuesday. Truist Financial raised their target price on Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a research note on Monday, August 24th. Finally, Citigroup cut their price target on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $31.53.

Hims & Hers Health Trading Down 5.1%

Shares of HIMS stock opened at $19.76 on Tuesday. The company has a market capitalization of $4.61 billion, a P/E ratio of -23.81 and a beta of 2.53. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $40.99. The company has a quick ratio of 0.87, a current ratio of 0.92 and a debt-to-equity ratio of 3.85. The firm has a 50-day moving average price of $27.77 and a 200 day moving average price of $26.75.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 9th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.03). Hims & Hers Health had a negative return on equity of 9.62% and a negative net margin of 6.65%. The firm had revenue of $890.37 million for the quarter, compared to analyst estimates of $893.13 million. During the same period in the previous year, the business posted $0.06 EPS. The business’s quarterly revenue was up 48.6% on a year-over-year basis. Research analysts forecast that Hims & Hers Health will post -0.21 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total transaction of $398,226.53. Following the transaction, the chief operating officer owned 456,660 shares of the company’s stock, valued at approximately $12,964,577.40. This represents a 2.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 25,111 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $27.55, for a total value of $691,808.05. Following the completion of the transaction, the insider owned 313,964 shares in the company, valued at $8,649,708.20. The trade was a 7.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 133,905 shares of company stock worth $3,826,977. Company insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently added to or reduced their stakes in the company. AlphaGrep UK Ltd bought a new stake in Hims & Hers Health during the 3rd quarter worth about $435,000. First Trust Advisors LP boosted its stake in shares of Hims & Hers Health by 369.8% in the 3rd quarter. First Trust Advisors LP now owns 239,624 shares of the company’s stock valued at $7,138,000 after purchasing an additional 188,615 shares during the last quarter. Creek Drive Management Group LLC boosted its stake in shares of Hims & Hers Health by 70.9% in the 3rd quarter. Creek Drive Management Group LLC now owns 100,000 shares of the company’s stock valued at $2,979,000 after purchasing an additional 41,500 shares during the last quarter. Cibc World Market Inc. boosted its stake in shares of Hims & Hers Health by 46.3% in the 3rd quarter. Cibc World Market Inc. now owns 91,202 shares of the company’s stock valued at $2,717,000 after purchasing an additional 28,854 shares during the last quarter. Finally, Western Wealth Management LLC grew its position in shares of Hims & Hers Health by 6.8% during the 3rd quarter. Western Wealth Management LLC now owns 9,072 shares of the company’s stock worth $270,000 after buying an additional 580 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health News Roundup

Here’s some of the latest news about HIMS:

• Negative Sentiment: Lower fourth-quarter and 2026 adjusted EBITDA guidance adds to the earnings disappointment, signaling weaker near-term profitability expectations. Hims & Hers earnings guidance
• Negative Sentiment: The FTC privacy case widened, with five states joining. The added scrutiny over alleged privacy and billing practices creates potential legal costs and reputational risk. Five states join FTC case
• Negative Sentiment: Analyst commentary has also turned cautious, including pessimistic forecasts from Needham and Jefferies and a Hold rating from Morgan Stanley, reinforcing concerns about the outlook. Needham forecast Jefferies forecast

Hims & Hers Health Company Profile

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.